Crescita Therapeutics Inc. (CRRTF) Research

Crescita Therapeutics Inc. operates as a specialized dermatology firm, offering a diverse portfolio that includes both over-the-counter skincare solutions and prescription pharmaceutical products. Its market reach extends across Canada, the United States, and other international territories. The company's operations are segmented into three core divisions: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. A key differentiator for Crescita lies in its proprietary platform technologies, MMPE and DuraPeel, which are utilized for formulating topical treatments, including those containing cannabis and hemp. Among its prescription offerings is Pliaglis, a topical local anesthetic cream designed to provide dermal analgesia on unbroken skin prior to minor dermatological procedures. The company's development pipeline features CTX-101, a Phase III topical corticosteroid for plaque psoriasis that incorporates MMPE technology, and CTX-102, a Phase I topical formulation, also leveraging MMPE, for an undisclosed dermatological condition. Additionally, several pre-clinical dermatology formulations are under development, applying MMPE technology for various skin diseases. In the non-prescription category, Crescita provides an extensive range of skincare items such as facial creams, cleansers, exfoliants, masks, serums, and sun protection products. These address common skin concerns like aging, acne, rosacea, pigmentation, dehydration, and sensitivity. Its brand lineup includes Laboratoire Dr Renaud for general skincare, Pro-Derm for anti-aging treatments often used with medical procedures, Alyria for targeting diverse skincare issues, and Dermazulene, primarily catering to Asian consumers. The company also offers NCTF 135 HA, a solution aimed at revitalizing skin quality and reducing fine lines. Crescita Therapeutics engages in strategic collaborations, exemplified by its development and licensing agreement with Sundial Growers Inc. for cannabis product development, a commercialization license with Cantabria Labs Inc., and a development and commercialization license with Taro Pharmaceuticals Inc. Established in 2016, Crescita Therapeutics Inc. maintains its headquarters in Laval, Canada.

Open Crescita Therapeutics Inc. (CRRTF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.